Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 5355

1.

Ursodiol.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

2.

A Complex Case of Cholestasis in a Patient with ABCB4 and ABCB11 Mutations.

Cardoso MF, E Branco JC, Anapaz V, Rodrigues CG, Carvalho R, Horta D, Martins A, Reis J.

GE Port J Gastroenterol. 2018 Jun;25(4):189-194. doi: 10.1159/000484612. Epub 2017 Nov 25.

PMID:
29998165
3.

Biliary transporter gene mutations in severe intrahepatic cholestasis of pregnancy: diagnostic and management implications.

Yeap SP, Harley H, Thompson R, Williamson KD, Bate J, Sethna F, Farrell G, Hague WB.

J Gastroenterol Hepatol. 2018 Jul 10. doi: 10.1111/jgh.14376. [Epub ahead of print]

PMID:
29992621
4.

Transport Mechanism of Ursodeoxycholic Acid in Human Placental BeWo Cells.

Xia Y, Dong Y, Zhao X, Di L, Li J.

Biopharm Drug Dispos. 2018 Jul 5. doi: 10.1002/bdd.2150. [Epub ahead of print]

PMID:
29978488
5.

Magnetic resonance imaging evidence of hippocampal structural changes in patients with primary biliary cholangitis.

Mosher VAL, Swain MG, Pang JXQ, Kaplan GG, Sharkey KA, MacQueen GM, Goodyear BG.

Clin Transl Gastroenterol. 2018 Jul 6;9(7):169. doi: 10.1038/s41424-018-0038-z.

6.

IgG4-related retroperitoneal fibrosis overlapping with primary biliary cirrhosis and primary Sjögren's syndrome: A case report.

Huang X, Lu B, Li M, Fan Y, Zhang L.

Medicine (Baltimore). 2018 Jun;97(26):e11303. doi: 10.1097/MD.0000000000011303.

7.

Hepatoprotective Effect of San-Cao Granule on Con A-Induced Liver Injury in Mice and Mechanisms of Action Exploration.

Yang Y, Zhang P, Wang Y, Wei S, Zhang L, Wang J, Lu X, Zhou H, Li R, Wen J, Zhou X, Li H, Li K, Zhao Y.

Front Pharmacol. 2018 Jun 12;9:624. doi: 10.3389/fphar.2018.00624. eCollection 2018.

8.

The role of bile acids in cellular invasiveness of gastric cancer.

Wu YC, Chiu CF, Hsueh CT, Hsueh CT.

Cancer Cell Int. 2018 May 21;18:75. doi: 10.1186/s12935-018-0569-0. eCollection 2018.

9.

A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity.

Nguyen HH, Khathlan A, Fritzler MJ, Swain MG.

BMC Gastroenterol. 2018 Jun 25;18(1):97. doi: 10.1186/s12876-018-0826-7.

10.

Assessment of liver disease in cystic fibrosis.

Davison S.

Paediatr Respir Rev. 2018 May 18. pii: S1526-0542(18)30071-X. doi: 10.1016/j.prrv.2018.05.010. [Epub ahead of print] Review.

PMID:
29933897
11.

Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Bahar R, Wong KA, Liu CH, Bowlus CL.

Gastroenterol Hepatol (N Y). 2018 Mar;14(3):154-163.

12.

Ursodeoxycholic acid versus phenobarbital for cholestasis in the Neonatal Intensive Care Unit.

Lewis T, Kuye S, Sherman A.

BMC Pediatr. 2018 Jun 20;18(1):197. doi: 10.1186/s12887-018-1167-y.

13.

Microbiome and Bile Acid Profiles in Duodenal Aspirates from Cirrhotics: The Microbiome, Microbial Markers and Liver Disease Study.

Jacobs JP, Dong TS, Agopian V, Lagishetty V, Sundaram V, Noureddin M, Ayoub W, Durazo F, Benhammou J, Enayati P, Elashoff D, Goodman MT, Pisegna J, Hussain S.

Hepatol Res. 2018 Jun 20. doi: 10.1111/hepr.13207. [Epub ahead of print]

PMID:
29923681
14.

Hepatic actinomycosis with immunoglobulin G4-related liver disease: A case report.

Lee JH, Kim HS, Kim JS, Lee DK, Lim JH.

Medicine (Baltimore). 2018 Jun;97(24):e11146. doi: 10.1097/MD.0000000000011146.

15.

Cellulase, Coca-Cola®, pancreatin and ursodeoxycholic acid in the dissolution of gastric bezoars: why not all together?

Cerezo Ruiz A, Domínguez Jiménez JL, Uceda-Vaño A.

Rev Esp Enferm Dig. 2018 Jul;110(7):472-473. doi: 10.17235/reed.2018.5617/2018.

16.

Circulating Fibroblast Growth Factor 19 in Portal and Systemic Blood.

Johansson H, Mörk LM, Li M, Sandblom AL, Björkhem I, Höijer J, Ericzon BG, Jorns C, Gilg S, Sparrelid E, Isaksson B, Nowak G, Ellis E.

J Clin Exp Hepatol. 2018 Jun;8(2):162-168. doi: 10.1016/j.jceh.2017.07.001. Epub 2017 Jul 28.

PMID:
29892179
17.

Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment.

Chen J, Xue D, Gao F, Tao L, Li Y, Zhang Q, Wang R, Sun L, Yang X, Liu Y, Zhu B, Niu S, Wang X.

Eur J Gastroenterol Hepatol. 2018 Jun 8. doi: 10.1097/MEG.0000000000001186. [Epub ahead of print]

PMID:
29889683
18.

[Relationship between phenotype and genotype of ABCB11 deficiency in siblings and literature review].

Peng XR, Lu Y, Zhang MH, Li LT, Xie XB, Gong JY, Wang JS.

Zhonghua Er Ke Za Zhi. 2018 Jun 2;56(6):440-444. doi: 10.3760/cma.j.issn.0578-1310.2018.06.007. Chinese.

PMID:
29886607
19.

Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.

Sedki M, Levy C.

Curr Gastroenterol Rep. 2018 Jun 9;20(7):29. doi: 10.1007/s11894-018-0635-8. Review.

PMID:
29886518
20.

Metformin treatment prevents gallstone formation but mimics porcelain gallbladder in C57Bl/6 mice.

Dorvash MR, Khoshnood MJ, Saber H, Dehghanian A, Mosaddeghi P, Firouzabadi N.

Eur J Pharmacol. 2018 Jun 5;833:165-172. doi: 10.1016/j.ejphar.2018.06.002. [Epub ahead of print]

PMID:
29883669

Supplemental Content

Loading ...
Support Center